Tag Archives: BAYRY

best upcoming stocks to invest in

SAN FRANCISCO A 2014 outing by a group of male and female Uber executives to a Korean karaokebar where women with pinned numbers were selected by male guestshas put a controversial member of the ride-hailing company’s top ranks back in the spotlight.

Emil Michael, who in the fall of that yearsuggested that the personal information of journalists who weren’t supportive of Uber be investigated, three weeks ago told a former girlfriend of CEO Travis Kalanick that she should sanitize the story of the outing, according to a report Friday in The Information.

The woman, Gabi Holzwarth, 27, said that Michael repeatedly asked her to keep details of the mid-2014 Seoul outing from reporters, including the fact that the venue featured women with numbers pinned on them. Some of the male Uber executives present selected women to drink with. Holzwarth and Kalanick left after about an hour. A female Uber marketing manager later complained to human resources about the incident. p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 11.0px Helvetica}span.s1 {font-kerning: none}

best upcoming stocks to invest in: (SHF)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    In March 2012, Schiff Nutrition International Inc. (NYSE: SHF) acquired the company for $150 million in cash.

    The product is still on the market today, found at most local drug stores. It is advertised now, however, as a nutritional supplement that does not, if taken alone, ward off viruses.

best upcoming stocks to invest in: J.M. Smucker Company (The)(SJM)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    The Pillsbury Doughboy is the mascot of the Pillsbury Company, which is owned by General Mills (NYSE: GIS) and J.M. Smucker (NYSE: SJM). The Doughboy was created by Pillsburys advertising agency almost 50 years ago. Pikachu are characters owned by The Pokemon Company International and appear in card games, video games, TV shows, movies and comic books. Founded in 1998, the Japanese company has achieved total games sales of almost 280 million. SpongeBob SquarePants was created for Nickelodeon, which is owned by Viacom (NASDAQ: VIA). The show premiered in 1999 and has spawned movies, video games and theme park rides. Ronald McDonald is a c

  • [By Teresa Rivas]

    J.M. Smucker(SJM) is falling Monday, after Morgan Stanley’sMatthew Grainger and his team cut their rating on the stock, citing pricing pressures from Wal-Mart (WMT) and growing competition from private-labels.

    Getty Images

    Grainger slash Smucker to Underweight from Equal Weight, and shaved $6 off his price target, to $126. He also cites what he calls “sustained” challenges in both its coffee and pet food business, as well as“below-average strategic optionality.”

    At the same time, he also upgraded Pinnacle Foods (PF) to Overweight from Equal Weight, and raised his price target to $63 from $58, on its double-digit earnings growth and what he sees as superior execution.

    Nonetheless, he sees many of the packaged food companies in his coverage, from Smucker to Pinnacle, as subject to pressure from Wal-Mart and off-brand rivals. From the note:

    Walmart comprises ~22% of sales across our coverage, a figure that has increased in recent years even as the retailers total grocery sales have grown at an even faster 4% CAGR. With Food margins expected to expand meaningfully, we believe this only enhances Walmart’s negotiating leverage going forward. SJM, Dean Foods (DF), and General Mills (GIS) are most at risk in the current environment, in our view.

    Recent scanner data points to a positive inflection in private label trends (share up ~30 bps L12W) across a range of center-store categories, a dynamic we believe could intensify in an increasingly competitive retail grocery landscape. Our analysis of recent trends points to the most meaningful underperformance vs. private label at GIS, SJM, ConAgra (CAG), and Campbell Soup (CPB), while only PF has outperformed in recent weeks.

    Smucker is down 1.1% to $127.95 this morning, while Pinnacle is up 0.8% to %48.47.

best upcoming stocks to invest in: Marsh & McLennan Companies, Inc.(MMC)

Advisors’ Opinion:

  • [By Reuters]

    Wendy Maeda/The Boston Globe via Getty Images
    NEW YORK — Walgreen is moving 120,000 employees to a private health insurance exchange from coverage provided directly from carriers, the company will announce Wednesday.
    The pharmacy chain will join 17 other large employers on the Aon Hewitt Corporate Health Exchange as part of a growing movement to offer employees fixed dollar amounts to purchase their own plans on such exchanges.
    The end-cost to employees depends on the plan chosen, but they typically get more options than under traditional arrangements. Private exchanges mimic the coverage mandated as part of the Affordable Care Act. Enrollment in the public exchanges starts Oct. 1.
    “What happens to employer contributions over time? Will they put in as much as they put in the past? These are unanswered questions but potential negatives,” says Paul Fronstin, a senior research associate with the Employee Benefit Research Institute. The benefit to Walgreen and other employers is unknown at this point, as their cost-savings aren’t clear.
    Of the 180,000 Walgreen (WAG) employees eligible for health care insurance, 120,000 opted for coverage for themselves and 40,000 family members. Another 60,000 employees, many of them working part-time, weren’t eligible for health insurance.
    Aon Hewitt (AON) says other participants in its program include retailer Sears Holding (SHLD) and Darden Restaurants (DRI). These new additions raise enrollment to 330,000 from 100,000 last year, and Aon Hewitt estimates enrollment will jump to 600,000 next year, a fivefold increase from 2012.
    By 2017, nearly 20 percent of employees nationwide could get their health insurance through a private exchange, according to Accenture Research (ACN). A recent report by the National Business Group on Health said that 30 percent of large employers are considering moving active employees to exchanges by 2015.

    Other major providers of private exchanges include Mercer, a division of Marsh & Mc

best upcoming stocks to invest in: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    A very risky Phase 3 drug for high cholesterol, anacetrapib, is listed and is in Phase 3; but several others of the class have failed, and there’s little reason to expect a success here (but you never know). Finally, a partnered heart failure drug that is also in Phase 3, vericiguat, is partnered with Bayer (OTCPK:BAYRY). This compound failed its primary endpoint in Phase 2. Yet, the partners agreed that there was hope for the highest of the three doses. Thus, I view this drug as a very high risk Phase 3 product. Maybe it will be successful and blockbuster, but it’s no sure thing.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

  • [By Maxx Chatsko]

    BeforeBayer(NASDAQOTH: BAYRY)arrived onto the scene, I viewedMonsanto(NYSE: MON)as an intriguing growth stock. It has a rich history of delivering value to shareholders and continues to hold a dominant technological edge over key competitors in crop protection products, seeds, and traits. While little has changed its promising pipeline and portfolio, the pending acquisition throws a wrench in anyone’s plans to start or add to a position. Uncertainty stemming from the merger provides several terrible reasons to buy Monsanto at this time.

best upcoming stocks to invest in: Pound/Rand(PX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:

    In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…

    Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).

    Normal high single digit EPS growth projected for both in 2017 vs 2016: Four large firms serve 70%+ of the global merchant gas market, and price normally contributes ~2% to growth. Customer older captive units being outsourced contributes another 2%. Secular drivers for oxygen include energy savings (i.e. O2 burns more efficiently than air), life sciences (healthcare & microbial processes) nitrogen secular drivers include increasing purity requirements (food freezing & semiconductors). Topline growth ~2x global GDP more normal, with EPS growth ~2x sales growth due to high fixed costs (key variable costs are inexpensive air & power).

    Financial crisis demand drop was only a few %, in line with global GDP drop Most chemicals volumes dropped 10%+ (some 40%

us stock exchange

September Corn is trading at 357 3/4, down 9 1/4 cents/bushel. December Corn is trading at 354 1/2, down 8 3/4 cents/bushel.

Corn futures have extended the session losses. Market talk about weather is constant.

The weekly corn crop condition report showed 76 percent of the crop was rated good to excellent versus 76 percent last week and 69 percent a year ago. The ten year average at this time of year is 64 percent.

Posted-In: Corn futuresFutures Commodities Markets

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

 
Related Articles Citi Says Netflix Q2 Results, Guidance Missed Even The Most Conservative Forecasts 7 Biggest Price Target Changes For Tuesday Lean Hog Futures Little Lower

us stock exchange: Yum! Brands, Inc.(YUM)

Advisors’ Opinion:

  • [By Rich Duprey]

    Yet pizza seems to be where real innovation is happening, because it’s not just Domino’s that has found success with digital technology, but Pizza Hut is alsobecoming a leader in showing just how far merchants can take artificial intelligence.The Yum! Brands (NYSE:YUM) pizza chain is still in the midst of a turnaround like the one Domino’s needed a few years back, and it is counting on technology to do it.

  • [By Daniel B. Kline]

    While its closest rivals Domino’s (NYSE:DPZ) and Papa John’s (NASDAQ:PZZA) have steadily delivered impressive growth in the United States Yum! Brands (NYSE:YUM) Pizza Hut has struggled.

  • [By WWW.GURUFOCUS.COM]

    McDonald’s is a fast-food service restaurant with more than 36 thousand restaurants in around 100 countries. With a market cap of $100 billion, the company has the largest position in the fast-food industry in the U.S., with Yum Brands (NYSE:YUM) being its closest competitor. The company sells burgers, fries and sandwiches with the vision of providing great taste, modern choices and real ingredients. McDonald’s is constantly trying to find new ways to strengthen the nutritional profile of its menu items while maintaining taste.

us stock exchange: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    A very risky Phase 3 drug for high cholesterol, anacetrapib, is listed and is in Phase 3; but several others of the class have failed, and there’s little reason to expect a success here (but you never know). Finally, a partnered heart failure drug that is also in Phase 3, vericiguat, is partnered with Bayer (OTCPK:BAYRY). This compound failed its primary endpoint in Phase 2. Yet, the partners agreed that there was hope for the highest of the three doses. Thus, I view this drug as a very high risk Phase 3 product. Maybe it will be successful and blockbuster, but it’s no sure thing.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.

us stock exchange: Rigel Pharmaceuticals Inc.(RIGL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares dropped 22 percent to $2.52 after the company reported results from the second FIT Phase 3 study for fostamatinib. The company disclosed that the study did not meet primary endpoint.

us stock exchange: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

  • [By Scott Levine]

    Climbing nearly 6% through January, the price of gold outpaced the meager gain — approximately 1% — of the S&P 500. Unsurprisingly, many of the market’s largest gold stocks enjoyed double-digit gains, including AngloGold Ashanti (NYSE:AU), Barrick Gold (NYSE:ABX), IAMGOLD (NYSE:IAG), and Royal Gold (NASDAQ:RGLD).

us stock exchange: Core Laboratories N.V.(CLB)

Advisors’ Opinion:

  • [By Craig Jones]

    Core Laboratories N.V. (NYSE: CLB) performed poorly and it is in the oil business. Cramer wouldn’t buy it, because he doesn’t want to recommend a stock in the oil and gas business.

  • [By Matthew DiLallo]

    Core Laboratories (NYSE:CLB) literally has its ear to the ground when it comes to deciphering what’s going on in the oil market. The company studies oil reservoirs, which tell it what’s happening with production, giving it a deep level of understanding on the supply side of the market. Core Labs takes what the reservoirs are saying, compares this with other data, and then blends it into an informed macro view of the oil market, which CEO David Demshur shared on the company’s recent quarterly earnings conference call. Here are five things he says the reservoirs are telling us about what’s really going on in the oil market.

  • [By Lisa Levin] Gainers
    Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
    Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
    Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
    Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
    Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
    Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
    AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
    Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
    Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
    Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
    Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

us stock exchange: The Middleby Corporation(MIDD)

Advisors’ Opinion:

  • [By Monica Gerson]

    Middleby Corp (NASDAQ: MIDD) is expected to post its quarterly earnings at $0.84 per share on revenue of $515.56 million.

    Jack in the Box Inc. (NASDAQ: JACK) is estimated to post its quarterly earnings at $0.70 per share on revenue of $360.22 million.

Top 10 Medical Stocks To Invest In Right Now

Thesis: The threat to enforce federal marijuana laws might backfire by pushing Congress to legalize marijuana on the federal level. While in the short term, marijuana related stocks might suffer, if legislation is passed and signed into law, it would not only ease fears, but also make it more likely that more states will follow along with the pot legalization trend. This will have a long term positive effect on marijuana stocks.

The Threat

Right now, even though it flies in the face of reality and evidence, marijuana is listed as a schedule one drug: a drug with high potential for abuse, no currently accepted medical treatment use in the U.S., and lack of accepted safety for use of the drug or substance under medical supervision.

President Trump has threatened to increase enforcement of federal cannabis laws. One might think that this will have a negative impact on marijuana and marijuana related stocks like Aurora Cannabis (OTCQB:ACBFF), General Cannabis (OTCQB:CANN), Americann (OTCQX:ACAN), and MassRoots (OTCQB:MSRT), and if implemented it probably would be devastating, both to publicly traded marijuana companies, and to local companies in regions that have legalized pot.

Top 10 Medical Stocks To Invest In Right Now: iShares Mortgage Real Estate Capped (REM)

Advisors’ Opinion:

  • [By Donald van Deventer]

    The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:

Top 10 Medical Stocks To Invest In Right Now: Callon Petroleum Company(CPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Top 10 Medical Stocks To Invest In Right Now: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    This type of spin-off is not uncommon among German companies, as they streamline their portfolios to focus on the where they have more competitive advantages in the long term. For instance, in the recent past, Siemens (OTCPK:SIEGY) has split out Osram (OTC:OSAGY) and Bayer (OTCPK:BAYRY) has performed the spin-off of Covestro (OTCPK:CVXTY), something that Rheinmetall is likely to do in the near future because its auto unit has reached peak margins, and therefore this is the best time to spin-off the business.

  • [By SEEKINGALPHA.COM]

    The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.

  • [By SEEKINGALPHA.COM]

    Fertilizers are only one input when it comes to farming, the equipment business has suffered, and seed suppliers are certainly concerned. Perhaps that is why another merger occurred last week between Monsanto (NYSE:MON) and Bayer (OTCPK:BAYRY). Bayer AG agreed to buy the U.S. seed manufacturer for $128 per share or approximately $47 billion creating a mammoth company with a combined value of almost $134.5 billion. The $128 per share price works out to a valuation of around 16 times earnings, which is cheap in a market where the average of S&P 500 stocks is trading at over 26.5 times earnings. However, the weakness in the agricultural sector caused disappointing earnings for Monsanto in the third quarter and a downbeat outlook for the future caused MON to accept Bayer’s bid. Bayer bought Monsanto at a low price, lowering the risk of the transaction for the German health care and agricultural giant.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

Top 10 Medical Stocks To Invest In Right Now: WPP plc(WPPGY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    WPP plc (WPPGY) — Most of WPP’s public websites were rendered inaccessible after the world’s biggest advertising group said its IT systems were the focus of a suspected cyberattack. Shares traded down almost 1% in early afternoon.

Top 10 Medical Stocks To Invest In Right Now: Entercom Communications Corporation(ETM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap radio broadcasting stock Entercom Communications Corp (NYSE: ETM), a potential peer of Emmis Communications Corporation (NASDAQ: EMMS), Saga Communications (NYSEAMERICAN: SGA) and troubled Cumulus Media (NASDAQ: CMLS), is the tenth most shorted stock on the NYSE with short interest of 45.06% according to Highshortnterest.com.

Top 10 Medical Stocks To Invest In Right Now: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Todd Campbell]

    Also, like in hepatitis C, competitors are attempting to win away market share. For example,ViiV Healthcare, a joint venture spearheaded by GlaxoSmithKline(NYSE:GSK), is actively pursuing new HIV therapies that could make it more difficult for Gilead Sciences to maintain its market share dominance. In December, ViiV announced that a single tablet, two-drug combination that includes Johnson & Johnson’s Edurant met its primary endpoint in phase 3 studies. A filing for FDA approval is slated for this year.

  • [By WWW.MONEYSHOW.COM]

    Donald Trump understands how regulation harms both businesses and consumers, discouraging innovation and raising costs. In a recent news conference, he pledged to “cut regulations by 75%, maybe more.”  This is good news indeed for drug companies like GlaxoSmithKline (GSK).

  • [By Paul Ausick]

    GlaxoSmithKline plc (NYSE: GSK) dropped about 1% Wednesday to post a new 52-week low of $34.52 after closing at $34.86 on Tuesday. The stock’s 52-week high is $44.54. Volume of around 4.8 million was about equal to the daily average. The company’s HIV drug is being challenged by a potentially better drug from competitor Gilead Sciences.

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

Top 10 Medical Stocks To Invest In Right Now: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Scott Levine]

    Climbing nearly 6% through January, the price of gold outpaced the meager gain — approximately 1% — of the S&P 500. Unsurprisingly, many of the market’s largest gold stocks enjoyed double-digit gains, including AngloGold Ashanti (NYSE:AU), Barrick Gold (NYSE:ABX), IAMGOLD (NYSE:IAG), and Royal Gold (NASDAQ:RGLD).

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

Top 10 Medical Stocks To Invest In Right Now: Chesapeake Utilities Corporation(CPK)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Tuesday, utilities shares slipped by just 0.5 percent. Meanwhile, top gainers in the sector included Pampa Energia S.A. (ADR) (NYSE: PAM), up 2 percent, and Chesapeake Utilities Corporation (NYSE: CPK) up 3 percent.

Top 10 Medical Stocks To Invest In Right Now: BanColombia S.A.(CIB)

Advisors’ Opinion:

  • [By Matt Smith]

    Bancolombia appears attractively priced
    Another Colombian company that appears under-valued is the Andean country’s largest commercial bank Bancolombia (NYSE: CIB  ) . For the year-to-date Bancolombia’s share price fell 17% because of a weak second quarter bottom-line. This decline was primarily caused by the bank’s net income plunging by 41% year-over-year because of mark-to-market losses caused by the value lost in the bank’s securities portfolio.

  • [By Javier Hasse]

    Analysts at Credit Suisse downgraded shares of Bancolombia SA (ADR) (NYSE: CIB) from Outperform to Neutral, while boosting their price target from $38 to $40.

  • [By Lisa Levin]

    Foreign Regional Banks: This industry declined 2 percent by 11:00 am with Bancolombia SA (ADR) (NYSE: CIB) moving down 3.7 percent. Bancolombia’s PEG ratio is 4.51.

Top 10 Medical Stocks To Invest In Right Now: Hudson Pacific Properties, Inc.(HPP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Friday.

    Douglas Dynamics Inc (NYSE: PLOW) – $0.2350 dividend, 2.9183 percent yield
    Tiffany & Co. (NYSE: TIF) – $0.4500 dividend, 2.6758 percent yield
    PulteGroup, Inc. (NYSE: PHM) – $0.0900 dividend, 1.7078 percent yield
    Leidos Holdings, Inc. (NYSE: LDOS) – $0.3200 dividend, 3.0851 percent yield
    Tupperware Brands Corporation (NYSE: TUP) – $0.6800 dividend, 4.1756 percent yield
    Hudson Pacific Properties Inc (NYSE: HPP) – $0.2000 dividend, 2.36

stock market

Stocks have thus far avoided another big down day following yesterday’s collapse, but it still feels like there’s another shoe to drop, doesn’t it?

Getty Images

So how will we know that the worst is over? Fundstrat technical analyst Robert Sluymer recommends “watching the downside leader, Energy, for evidence of decelerating,” particularly ExxonMobil (XOM) and Chevron (CVX). He explains:

Beyond the obvious defensive relative rotation underway favoring Bond proxies, Staples and Restaurants at the expense of Cyclicals and Financials, we are monitoring Energy closely. Why? Energy, peaked in relative performance terms in December and has since led Cyclicals lower. While it is premature to suggest an improvement is developing for the sector, the list of names making new multi-week relative lows has not expanded during recent market weakness. Although XOM and CVX are the most defensive names in the sector, relative performance is showing early signs of improving, as both names become tactically. Defensive exposure with an offensive option?

stock market: Madison Square Garden Inc.(MSG)

Advisors’ Opinion:

  • [By Monica Gerson]

    Madison Square Garden Co (NYSE: MSG) is estimated to report a quarterly loss at $0.34 per share on revenue of $325.53 million.

    Gogo Inc (NASDAQ: GOGO) is projected to report a quarterly loss at $0.42 per share on revenue of $137.58 million.

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Meanwhile, Mark Boyar, of The Boyar Value Fund, recommends another household name: Madison Square Garden (MSG). He thinks the Dolan family could take the company private.

stock market: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    You can torture the data many ways, of course, and there were some pharma price increases in the US, but apparently, they were not especially large. What hurt were discounting, especially for Xarelto, a Bayer (OTCPK:BAYRY) oral anticoagulant which JNJ markets in the US; and the diabetes Invokana line.

  • [By SEEKINGALPHA.COM]

    The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    This type of spin-off is not uncommon among German companies, as they streamline their portfolios to focus on the where they have more competitive advantages in the long term. For instance, in the recent past, Siemens (OTCPK:SIEGY) has split out Osram (OTC:OSAGY) and Bayer (OTCPK:BAYRY) has performed the spin-off of Covestro (OTCPK:CVXTY), something that Rheinmetall is likely to do in the near future because its auto unit has reached peak margins, and therefore this is the best time to spin-off the business.

  • [By SEEKINGALPHA.COM]

    Rivaroxaban was initially developed by Janssen, a subsidiary of Johnson & Johnson (NYSE:JNJ). It later entered an agreement with Bayer (OTCPK:BAYRY) to jointly complete the development process in 2005.

  • [By SEEKINGALPHA.COM]

    A very risky Phase 3 drug for high cholesterol, anacetrapib, is listed and is in Phase 3; but several others of the class have failed, and there’s little reason to expect a success here (but you never know). Finally, a partnered heart failure drug that is also in Phase 3, vericiguat, is partnered with Bayer (OTCPK:BAYRY). This compound failed its primary endpoint in Phase 2. Yet, the partners agreed that there was hope for the highest of the three doses. Thus, I view this drug as a very high risk Phase 3 product. Maybe it will be successful and blockbuster, but it’s no sure thing.

stock market: Conn's, Inc.(CONN)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Best Buy Co outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):

  • [By Chris Lange]

    Conn’s Inc. (NASDAQ: CONN) will share its latest quarterly earnings on Thursday. The consensus estimates call for a net loss of $0.07 per share and $413.12 million in revenue. Shares were at $6.84 on Fridays close, in a 52-week range of $6.54 to $34.60. The consensus price target is $13.17.

  • [By Lisa Levin]

    Conn's Inc (NASDAQ: CONN) shares were also up, gaining 32 percent to $11.18 after the company reported better-than-expected earnings for its fourth quarter.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday’s regular session.

    Pier 1 Imports Inc (NYSE: PIR) Dec16 5.0 Puts Sweep: 1191 @ ASK $0.80: 1354 traded vs 102 OI: $5.32 Ref
    Alcoa Inc (NYSE: AA) Jul16 9.5 Puts Sweep: 1494 @ ASK $0.13: 14k traded vs 6682 OI: $10.09 Ref
    Sarepta Therapeutics Inc (NASDAQ: SRPT) Jul16 10.0 Puts: 3536 @ ASK $0.50: 5506 traded vs 54k OI: Earnings 8/4 $22.50 Ref
    Tableau Software Inc (NYSE: DATA) Jul16 47.5 Puts Sweep: 837 @ ASK $0.30: 995 traded vs 37 OI: Earnings 8/3 $50.60 Ref
    Yandex NV (NASDAQ: YNDX) Aug16 18.0 Puts Sweep: 532 @ ASK $0.30: 2143 traded vs 78 OI: Earnings 7/28 Before Open $22.02 Ref
    Wolverine World Wide, Inc. (NYSE: WWW) Aug16 22.5 Puts: 719 @ ASK $1.35: 1032 traded vs 0 OI: Earnings 7/19 $22.22 Ref
    Conn's Inc (NASDAQ: CONN) Jan17 5.0 Puts Sweep: 605 @ ASK $0.85: 1355 traded vs 3132 OI: $7.16 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Lisa Levin]

    Conn’s Inc (NASDAQ: CONN) shares dropped 23 percent to $9.03 as the company reported downbeat quarterly results. Conn’s posted a Q1 loss of $0.31 per share on revenue of $389.1 million.

  • [By Lisa Levin]

    Wednesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Conn's Inc (NASDAQ: CONN) and Wyndham Worldwide Corporation (NYSE: WYN).

stock market: Leading Brands Inc(LBIX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares dropped 13 percent to $1.99 following Q2 results. Leading Brands posted Q2 EBITDAS of $0.00 per share, compared to $0.09 per share during the same period last year.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 66 percent to $2.49 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares were also up, gaining 145 percent to $3.31 on no formal news from company. The stock rallied 215 percent over Tuesday and Wednesday of this week amid trader speculation stock could be sympathy play on move higher in Helios & Matheson. However, Leading Brands shares sold off 27 percent on Thursday.

stock market: Telephone and Data Systems, Inc.(TDS)

Advisors’ Opinion:

  • [By Monica Gerson]

    Telephone & Data Systems, Inc. (NYSE: TDS) is projected to report its quarterly earnings at $0.10 per share on revenue of $1.26 billion.

    PharMerica Corporation (NYSE: PMC) is estimated to report its quarterly earnings at $0.43 per share on revenue of $509.45 million.

china stock market

(AP Photo/Sheridan Press, Jordan Edgcomb)

This is not an April Fool’s joke.

If you are counting on Public Service Loan Forgiveness – the federal program that forgives your student loan debt after 10 years of qualifying work in public service and 120 consecutive student loan payments – then pay close attention.

As first reported by the New York Times, a student loan borrower’s acceptance into a federal student loan forgiveness program may not be binding and could be rescinded by the U.S. Department of Education.

In a legal filing March 23, the Education Department said that student loan borrowers could not rely on the approval letters sent by the program’s administrator, FedLoan Servicing, because any approvals are considered tentative.

Four student loan borrowers (and the American Bar Association) sued the Education Department to seek reinstatement of their eligibility for the Public Service Loan Forgiveness Program. The plaintiffs claim they initially qualified for Public Service Loan Forgiveness, only to have the decision subsequently reversed.

china stock market: Dominion Resources, Inc.(D)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from National Grid plc (ADR) (NYSE: NGG) and Dominion Resources, Inc. (NYSE: D).

  • [By David Dittman]

    But power generators across the country, including Dominion Resources Inc (NYSE: D) in Virginia and Southern Company (NYSE: SO) in the Southeast, are taking significant steps to boost their solar capacity.

  • [By Shauna O’Brien]

    JP Morgan reported on Friday that it has raised its rating on energy producer Dominion Resources, Inc. (D).

    The firm has upgraded D from “Neutal” to “Overweight,” and has given the company a $68 price target. This price target suggests a 12% increase from Thursday’s closing price of $59.78.

    Analysts see midstream growth and its MLP formation adding value to existing assets.

    Dominion Resources shares were up $1.02, or 1.71%, during pre-market trading Friday. The stock is up 15% YTD.

china stock market: Cannabis Science, Inc. (CBIS)

Advisors’ Opinion:

  • [By Matthew Briar]

    Look out Cannabis Science Inc (OTCMKTS:CBIS), and step aside Medical Marijuana Inc (OTCMKTS:MJNA). There’s a new cannabis name on the scene…. Algae Dynamics Corp. (OTCMKTS:ADYNF). It may not be known (or named) like its marijuana peers, but give it time. This small cap company has a very big idea, and it’s going to sprout soon.

    Yes, Algae Dynamics is an algae company. It’s not just an algae company though.

    Algae Dynamics is the owner of the proprietary BioSilo ™ process. BioSilo is a way of growing algae quickly and effectively…. a mix of an open-pond system and a photobioreactor, which is a light-driven approach to growing algae. It can be viewed as a “best of both worlds” approach, lowering the typical cost of algae farming, while the modular design makes it easy to maintain.

    The company could go a lot of directions with the technology, Most of the tens of thousands of species of algae are rather flexible in how they can be purposed, and what they can become. Algae Dynamics is first focused on the development of two kinds of products though…. Chlorella, and Omega-3.

    Chlorella is a type of microalgae that can be processed into a consumable powder by drying it until it takes a powder form, similar to coffee. Chlorella is rich in minerals, prebiotics, vitamins, and other nutritional substances. It can be added to a baked goods and a number of other products, or taken as a supplement on its own. Chlorella is used in over 1,000 products in the food and beverage markets. Algae Dynamics estimates the global Chlorella market was $210.3 million in 2014 and is expected to reach $265.5 million in 2018.

    Despite a market for Chlorella in North America, there are no commercial North American producers of it.

    Due to its health benefits, Omega-3 oil can be added to a very wide range of products. Consumers are increasingly aware of these benefits too, leading to substantial growth in the industry; health supplements compr

  • [By Peter Graham]

    A long term performance chart shows GW Pharmaceuticals PLC outperforming other marijuana stocks like Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA), but shares are also once again falling off from all-time highs:

  • [By Jim Robertson]

    When investors think of cannabinoid or marijuana stocks, they either think of better known stocks likeGW Pharmaceuticals PLC (NASDAQ: GWPH)and Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) that trade on bigger exchanges orCannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA) that are stilllisted on the OTC. However, there are other more indirect ways to invest in growing cannabinoid or marijuana acceptance.

china stock market: Francesca's Holdings Corporation(FRAN)

Advisors’ Opinion:

  • [By Lisa Levin] Related LOV Match Group And Spark Networks: A Valentine's Day Case Study 20 Biggest Mid-Day Losers For Thursday
    Related VKTX 15 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Losers For Wednesday Companies Reporting Before The Bell
    Canadian Solar Inc. (NASDAQ: CSIQ) is expected to report its quarterly earnings at $0.32 per share on revenue of $690.27 million.
    General Mills, Inc. (NYSE: GIS) is projected to report its quarterly earnings at $0.71 per share on revenue of $3.84 billion.
    Coca-Cola European Partners Plc (NYSE: CCE) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.72 billion.
    Lands' End, Inc. (NASDAQ: LE) is expected to report its quarterly earnings at $0.35 per share on revenue of $459.43 million.
    Francesca's Holdings Corp (NASDAQ: FRAN) is estimated to report its quarterly earnings at $0.37 per share on revenue of $145.91 million.
    Cheetah Mobile Inc (ADR) (NYSE: CMCM) is projected to report its quarterly earnings at $0.06 per share on revenue of $178.04 million.
    Neogen Corporation (NASDAQ: NEOG) is estimated to report its quarterly earnings at $0.27 per share on revenue of $90.05 million.
    Lennar Corporation (NYSE: LEN) is projected to post earnings for its first quarter.
    Fifth Street Asset Management Inc (NASDAQ: FSAM) is expected to report its quarterly earnings at $0.14 per share on revenue of $25.12 million.

     

  • [By Ben Levisohn]

    Francesca’s Holdings (FRAN) has jumped 5.4% to $11.00 after beating earnings forecasts.

    Restoration Hardware (RH) has tumbled 20% to $28.92 after slashing its full-year guidance. Restoration Hardware was also cut to Market Perform from Outperform at Telsey Advisory Group.

china stock market: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Rivaroxaban was initially developed by Janssen, a subsidiary of Johnson & Johnson (NYSE:JNJ). It later entered an agreement with Bayer (OTCPK:BAYRY) to jointly complete the development process in 2005.

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

  • [By SEEKINGALPHA.COM]

    You can torture the data many ways, of course, and there were some pharma price increases in the US, but apparently, they were not especially large. What hurt were discounting, especially for Xarelto, a Bayer (OTCPK:BAYRY) oral anticoagulant which JNJ markets in the US; and the diabetes Invokana line.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    This type of spin-off is not uncommon among German companies, as they streamline their portfolios to focus on the where they have more competitive advantages in the long term. For instance, in the recent past, Siemens (OTCPK:SIEGY) has split out Osram (OTC:OSAGY) and Bayer (OTCPK:BAYRY) has performed the spin-off of Covestro (OTCPK:CVXTY), something that Rheinmetall is likely to do in the near future because its auto unit has reached peak margins, and therefore this is the best time to spin-off the business.

china stock market: Las Vegas Sands Corp.(LVS)

Advisors’ Opinion:

  • [By Travis Hoium]

    But Las Vegas Sands Corp. (NYSE:LVS) may not have had as strong a quarter as competitors like Melco Crown Entertainment Ltd (NASDAQ:MPEL) and Wynn Resorts, Limited (NASDAQ:WYNN). We’ll have to wait until the latter two report earnings to see how market share is trending, but Las Vegas Sands left a lot to be desired from a growth perspective.

  • [By Ben Levisohn]

    Las Vegas Sands (LVS) has declined 1.1% to $58.60 despite beating earnings forecasts.

    O’Reilly Automotive (ORLY) has fallen 2.7% to $257.99 after missing earnings forecasts and lowering full-year guidance.

  • [By Rich Duprey]

    The big casinos certainly want to spend big. Las Vegas Sands (NYSE:LVS) says a new integrated resort in Japan will cost anywhere from $6 billion to $10 billion, two to three times more than it spent on building its brand new French-themed Parisian resort in Macau. MGM Resorts (NYSE:MGM) says it, too, could spend $10 billion for a new casino in Japan, quadruple the cost of its MGM Cotai that’s scheduled to open later this year. Wynn Resorts (NASDAQ:WYNN) hasn’t put a price tag on it yet, though it spent over $4 billion to open the Palace in Macau last August, but CEO Steve Wynn says the opportunity is “thoroughly delicious.”

  • [By Ben Levisohn]

    Wynn wasn’t the only Macau casino operator that took it on the chin today. Las Vegas Sands (LVS) tumbled 13% to $54.67, while Melco Crown Entertainment (MPEL) plunged 14% to $16.87, and MGM Resorts International (MGM) dropped 4.3% to $28.65.

  • [By WWW.THESTREET.COM]

    Cramer recalled how, in 2009, colleague Dan Fitzpatrick correctly identified Las Vegas Sands (LVS) as it broke out of its $10 a share funk and soared to $48, almost in a straight line. This technical move was brought on by Sands’ red-hot properties in Macau.

china stock market: Federated Investors, Inc.(FII)

Advisors’ Opinion:

  • [By Gregg Greenberg]

     Stocks of Federated Investors (FII) fell approximately 9% in 2015, yet Oja expects a big turnaround in 2016, once again due to the prospect of higher rates ahead. 

     

    "The money market fund business, which is unprofitable now, should become more profitable as rates rise because Federated has to reimburse for the servicing fees for these funds," said Oja, who also admires the fund company’s 3.5% dividend yield. 

     

    Oja added that Federated also has a "good core business of equity and fixed-income asset management."